Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Other Accumulated Expenses (2019 - 2025)

SRx Health Solutions' Other Accumulated Expenses history spans 7 years, with the latest figure at $7000.0 for Q2 2025.

  • For Q2 2025, Other Accumulated Expenses changed N/A year-over-year to $7000.0; the TTM value through Jun 2025 reached $7000.0, changed N/A, while the annual FY2024 figure was $149000.0, 49.32% down from the prior year.
  • Other Accumulated Expenses reached $7000.0 in Q2 2025 per SRXH's latest filing, down from $221000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.9 million in Q4 2021 to a low of $7000.0 in Q2 2025.
  • Average Other Accumulated Expenses over 4 years is $383428.6, with a median of $149000.0 recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: soared 720.0% in 2021, then tumbled 49.32% in 2024.
  • A 4-year view of Other Accumulated Expenses shows it stood at $1.9 million in 2021, then crashed by 84.35% to $294000.0 in 2023, then crashed by 49.32% to $149000.0 in 2024, then plummeted by 95.3% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Other Accumulated Expenses are $7000.0 (Q2 2025), $221000.0 (Q1 2025), and $149000.0 (Q4 2024).